134 related articles for article (PubMed ID: 26254201)
1. Can We Predict Sustained Virologic Response to Interferon α Therapy in Patients With Chronic Hepatitis Delta Virus Infection?
Scholtès C; Kumar R; Zoulim F
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2350-2. PubMed ID: 26254201
[No Abstract] [Full Text] [Related]
2. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
[TBL] [Abstract][Full Text] [Related]
3. Current management of delta hepatitis.
Rizzetto M
Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
[TBL] [Abstract][Full Text] [Related]
5. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
Lutterkort GL; Wranke A; Hengst J; Yurdaydin C; Stift J; Bremer B; Hardtke S; Keskin O; Idilman R; Manns MP; Dienes HP; Falk C; Wedemeyer H; Heidrich B
J Viral Hepat; 2018 Nov; 25(11):1384-1394. PubMed ID: 29888837
[TBL] [Abstract][Full Text] [Related]
6. Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta.
Ouzan D; Pénaranda G; Joly H; Halfon P
J Hepatol; 2013 Jun; 58(6):1258-9. PubMed ID: 23318602
[No Abstract] [Full Text] [Related]
7. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response.
Karaca C; Soyer OM; Baran B; Ormeci AC; Gokturk S; Aydin E; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S
Antivir Ther; 2013; 18(4):561-6. PubMed ID: 22976528
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline].
Horváth G; Hunyady B; Gervain J; Lengyel G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
Orv Hetil; 2014 Mar; 155 Suppl():25-36. PubMed ID: 24631887
[TBL] [Abstract][Full Text] [Related]
9. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
[TBL] [Abstract][Full Text] [Related]
10. Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine.
Mansour W; Ducancelle A; Le Gal F; Le Guillou-Guillemette H; Abgueguen P; Pivert A; Calès P; Gordien E; Lunel F
J Clin Virol; 2010 Jan; 47(1):97-9. PubMed ID: 19914127
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response.
Samiullah S; Bikharam D; Nasreen
World J Gastroenterol; 2012 Oct; 18(40):5793-8. PubMed ID: 23155322
[TBL] [Abstract][Full Text] [Related]
12. Authors' reply to Comment on "No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance" [Dig. Liver Dis.2014;46:348-52].
Visco-Comandini U; Lapa D; Taibi C; Angeletti C
Dig Liver Dis; 2014 Aug; 46(8):762. PubMed ID: 24890620
[No Abstract] [Full Text] [Related]
13. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
[TBL] [Abstract][Full Text] [Related]
14. Comment on "No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance" by Ubaldo Visco-Comandini et al. [Dig. Liver Dis. 2014;46:348-52].
Keshvari M; Sharafi H; Alavian SM
Dig Liver Dis; 2014 Aug; 46(8):761-2. PubMed ID: 24815081
[No Abstract] [Full Text] [Related]
15. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
[TBL] [Abstract][Full Text] [Related]
16. Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa.
Maraolo AE; Minervini F; Tosone G
Aliment Pharmacol Ther; 2015 Mar; 41(6):595. PubMed ID: 25659214
[No Abstract] [Full Text] [Related]
17. Resolution of chronic hepatitis delta infection after five years of peginterferon-adefovir: lessons from a case report.
Brichler S; Setshedi M; Renou C
Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):e81-4. PubMed ID: 23433964
[TBL] [Abstract][Full Text] [Related]
18. Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa--authors' reply.
Koh C; Heller T
Aliment Pharmacol Ther; 2015 Mar; 41(6):595-6. PubMed ID: 25659215
[No Abstract] [Full Text] [Related]
19. Meta-analysis: antiviral treatment for hepatitis D.
Triantos C; Kalafateli M; Nikolopoulou V; Burroughs A
Aliment Pharmacol Ther; 2012 Mar; 35(6):663-73. PubMed ID: 22273482
[TBL] [Abstract][Full Text] [Related]
20. Pegylated interferon therapy of chronic hepatitis D: in need of revision.
Rizzetto M; Smedile A
Hepatology; 2015 Apr; 61(4):1109-11. PubMed ID: 25348580
[No Abstract] [Full Text] [Related]
[Next] [New Search]
